drugset / Trial / NCT06006273
A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors
RandomizedSingle-groupOpen-labelTreatment
Summary
To find the recommended dose of eribulin that can be given in combination with irinotecan and temozolomide to treat relapsed and/or refractory solid tumors.
Timeline
- Start
- 2023-08-16
- Primary completion
- 2026-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eribulin | Small molecule | — | Intravenous |
| Background | Irinotecan | Small molecule | — | Intravenous |
| Background | Temozolomide | Small molecule | — | Oral |